News
Asahi Kasei buys antiviral firm Aicuris for €780m
Asahi Kasei has agreed to buy Germany's Aicuris for around $920m, adding an antiviral drug it hopes will help drive its 2030 pharma sales to $1.9bn.
News
Changes at the top of Sarepta, Alkermes, as CEOs depart
Two long-serving pharma CEOs have announced their departures, as Sarepta's Doug Ingram and Alkermes' Richard Pops announce their retirement.
News
Novo Nordisk beefs up in oral obesity drugs with Vivtex deal
Novo Nordisk is leaving no stone unturned in its bid to maintain its position in weight-loss therapies as it signs a $2.1bn alliance with Vivtex.
News
GSK grows pipeline with 35Pharma takeover, Frontier deal
GSK CEO Luke Miels signs a pair of pipeline-expanding deals, and the first acquisition on his watch, as the group prepares for a looming patent cliff.
News
Astellas bets on Vir cancer drug, and other licensing deals
Our latest round-up of pharma licensing deals features assets from Vir Biotech, Harbour BioMed, Unnatural Products, Genhouse, and CSL.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
